Sangamo Therapeutics, Inc.

Good day, and thank you for standing by. And welcome to Sangamo fourth quarter 2023 teleconference. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you'll need to press R11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 11 again. Please be advised that today's conference is being recorded. I'd now like to hand the conference over to your speaker today, Louise Wilkie, Vice President of Investor Relations, Corporate Communications. Please go ahead.

Good afternoon.

Thank you for joining us on the call today, where we'll be not only sharing our progress across the business, but also sharing exciting new data that we believe reinforce our decision to become a neurology-focused genomic medicine company. Slides from today's presentation, which are being screen shared through the live webcast link, can be found on our website, sangamo.com, under the Investors and Media sections of the Events and Presentations page. This call includes forward-looking statements regarding Sangamo's current expectations. These statements include, but are not limited to, statements relating to the therapeutic and commercial potential of our product candidates and engineered capsids, the anticipated plans and timelines of Sangamo and our collaborators for regulatory submissions, initiating and conducting clinical trials, screening and dosing patients, and presenting clinical data, advancement of our product candidates, anticipated submissions, feedback from, and interactions with regulatory agencies, advancement of preclinical programs to the clinic, our strategic reprioritization and reallocation of resources and the anticipated benefits thereof, plans to partner certain of our programs, the sufficiency of our resources, cash runway, and plans to seek additional capital, and the timing of related updates. Our initial financial guidance for 2024 and estimates of 2024 operating expenses, upcoming catalysts and milestones, and other statements that are not historical facts. Actual results may differ materially from what we discussed today. These statements are subject to certain risks and uncertainties that are discussed in our filings of the SEC, specifically in our annual report on Form 10-K for the fiscal year ended December 31, 2023 filed with the SEC. The forward-looking statements stated today are made as of this date, and we undertake no duty to update such information except as required by law. On this call, we discuss our non-GAAP operating expenses. Reconciliation of this measure to our GAAP operating expenses can be found in our press release, which is available on our website. Please note that all forward-looking statements about our future plans and expectations, including our financial guidance, are subject to our ability to secure adequate additional funding. On today's call, I'm joined by Sandy McRae, Chief Executive Officer, Patricia Durababu, Chief Financial Officer, Amy Pooler, Head of Research, Greg Davis, Head of Technology, and Natalie Dubar-Stringfellow, Chief Development Officer. Now, I'll turn the call over to our CEO, Sandy McRae.